# Cryo Cell International Inc: overview CCEL · NYSE · CIK 862692 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Nov 30 Pages: [Overview](/companies/ccel.md) · [Financials](/companies/ccel/financials.md) · [Filings](/companies/ccel/filings.md) · [Insiders](/companies/ccel/insiders.md) Latest reported revenue: [$7.8m](/filings/0001193125-26-419156.md) for Q3 FY2026, three months to 2026-08-31, from the 10-Q filed Oct 9, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001193125-26-419156). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [8,024 d](/filings/0001193125-26-083096.md) | [7,969](/filings/0001193125-26-155057.md) | [7,929](/filings/0001193125-26-304834.md) | [7,825](/filings/0001193125-26-419156.md) | [7,843 d](/filings/0001193125-26-083096.md) | [7,683](/filings/0001193125-26-155057.md) | [7,776](/filings/0001193125-26-304834.md) | [7,824](/filings/0001193125-26-419156.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1.5%) d](/filings/0001193125-26-083096.md) | [13.3%](/filings/0001193125-26-155057.md) | [18.8%](/filings/0001193125-26-304834.md) | [24.3%](/filings/0001193125-26-419156.md) | [(50.6%) d](/filings/0001193125-26-083096.md) | [10.0%](/filings/0001193125-26-155057.md) | [15.4%](/filings/0001193125-26-304834.md) | [28.0%](/filings/0001193125-26-419156.md) | | Net margin | % | [(23.2%) d](/filings/0001193125-26-083096.md) | [3.5%](/filings/0001193125-26-155057.md) | [4.5%](/filings/0001193125-26-304834.md) | [9.6%](/filings/0001193125-26-419156.md) | [(48.7%) d](/filings/0001193125-26-083096.md) | [0.6%](/filings/0001193125-26-155057.md) | [7.1%](/filings/0001193125-26-304834.md) | [16.2%](/filings/0001193125-26-419156.md) | | Diluted EPS | $ per share | not reported | [0.03](/filings/0001193125-26-155057.md) | [0.04](/filings/0001193125-26-304834.md) | [0.09](/filings/0001193125-26-419156.md) | not reported | [0.01](/filings/0001193125-26-155057.md) | [0.07](/filings/0001193125-26-304834.md) | [0.16](/filings/0001193125-26-419156.md) | | Free cash flow | $k | [2,149 d](/filings/0001193125-26-083096.md) | [892](/filings/0001193125-26-155057.md) | [645 d](/filings/0001193125-26-304834.md) | [2,498 d](/filings/0001193125-26-419156.md) | [1,214 d](/filings/0001193125-26-083096.md) | [585](/filings/0001193125-26-155057.md) | [1,813 d](/filings/0001193125-26-304834.md) | [1,040 d](/filings/0001193125-26-419156.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-11-30) | FY2022 (2022-11-30) | FY2023 (2023-11-30) | FY2024 (2024-11-30) | FY2025 (2025-11-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [28.9](/filings/0000950170-23-005220.md) | [30.3](/filings/0000950170-24-022275.md) | [31.3](/filings/0000950170-25-030138.md) | [32.0](/filings/0001193125-26-083096.md) | [31.6](/filings/0001193125-26-083096.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [13.9%](/filings/0000950170-23-005220.md) | [13.3%](/filings/0000950170-24-022275.md) | [(39.3%)](/filings/0000950170-25-030138.md) | [10.9%](/filings/0001193125-26-083096.md) | [1.5%](/filings/0001193125-26-083096.md) | | Net margin | % | [7.2%](/filings/0000950170-23-005220.md) | [9.1%](/filings/0000950170-24-022275.md) | [(30.4%)](/filings/0000950170-25-030138.md) | [1.3%](/filings/0001193125-26-083096.md) | [(7.7%)](/filings/0001193125-26-083096.md) | | Diluted EPS | $ per share | [0.25](/filings/0000950170-23-005220.md) | [0.33](/filings/0000950170-24-022275.md) | [(1.14)](/filings/0000950170-25-030138.md) | [0.05](/filings/0001193125-26-083096.md) | [(0.30)](/filings/0001193125-26-083096.md) | | Free cash flow | $m | [6.1](/filings/0000950170-23-005220.md) | [(3.6)](/filings/0000950170-24-022275.md) | [2.1](/filings/0000950170-25-030138.md) | [3.6](/filings/0001193125-26-083096.md) | [5.2](/filings/0001193125-26-083096.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ccel/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SFI Advisors, LLC](/funds/1911308.md) | 2026-06-30 | $527.3k | 165,300 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $526.3k | 164,976 | | Added +3,452 | | [MassMutual Private Wealth & Trust, FSB](/funds/1103653.md) | 2026-06-30 | $354.2k | 111,035 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $147.7k | 46,273 | | Added +2,657 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $74.5k | 23,346 | | Unchanged | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $63.8k | 20,000 | | New +20,000 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $44.9k | 14,064 | | Added +4,046 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $21.4k | 6,696 | | Reduced −7,287 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $8.0k | 2,500 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.9k | 605 | | Added +4 | ## Recent filings [All 663 filings](/companies/ccel/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-13 | 21:00 ET | [DEF 14A](/filings/0001193125-26-420608.md) | Proxy statement, period 2026-10-27 | 0001193125-26-420608 | | 2026-10-09 | 20:30 ET | [10-Q](/filings/0001193125-26-419156.md) | Quarterly report, period 2026-08-31 | 0001193125-26-419156 | | 2026-09-14 | 20:30 ET | [8-K](/filings/0001193125-26-390647.md) | 8.01 Other events | 0001193125-26-390647 | | 2026-07-15 | 20:30 ET | [10-Q](/filings/0001193125-26-304834.md) | Quarterly report, period 2026-05-31 | 0001193125-26-304834 | | 2026-07-07 | 13:01 ET | [SCHEDULE 13D/A](/filings/0001493152-26-032265.md) | Ownership report, active investor, amended | 0001493152-26-032265 | | 2026-05-08 | 20:00 ET | [8-K](/filings/0001193125-26-214569.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-214569 | | 2026-04-14 | 21:00 ET | [10-Q](/filings/0001193125-26-155057.md) | Quarterly report, period 2026-02-28 | 0001193125-26-155057 | | 2026-03-25 | 01:54 ET | [SCHEDULE 13D](/filings/0001493152-26-012763.md) | Ownership report, active investor | 0001493152-26-012763 | | 2026-03-12 | 21:00 ET | [8-K](/filings/0001193125-26-104392.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-104392 | | 2026-02-27 | 22:01 ET | [10-K](/filings/0001193125-26-083096.md) | Annual report, period 2025-11-30 | 0001193125-26-083096 | ## Latest annual report [Form 10-K for the fiscal year ended Nov 30, 2025](/filings/0001193125-26-083096.md), filed Feb 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 862692 - Tickers: CCEL - Exchange: NYSE - SIC code: 8090 Services-Misc Health & Allied Services, NEC - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.